

Arnulf Stenzl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9196005/publications.pdf>

Version: 2024-02-01

233
papers

9,027
citations

61984

43
h-index

49909

87
g-index

240
all docs

240
docs citations

240
times ranked

8497
citing authors

#	ARTICLE	IF	CITATIONS
1	Definition of a Structured Training Curriculum for Robot-assisted Radical Cystectomy with Intracorporeal Ileal Conduit in Male Patients: A Delphi Consensus Study Led by the ERUS Educational Board. <i>European Urology Focus</i> , 2022, 8, 160-164.	3.1	21
2	Receptor Activator of NF Kappa B (RANK) Expression Indicates Favorable Prognosis in Patients with Muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2022, 8, 718-727.	3.1	0
3	Robotic Transrectal Computed Tomographic Ultrasound with Artificial Neural Network Analysis: First Validation and Comparison with MRI-Guided Biopsies and Radical Prostatectomy. <i>Urologia Internationalis</i> , 2022, 106, 90-96.	1.3	3
4	On the probability of lymph node negativity in pN0-staged prostate cancer – a theoretically derived rule of thumb for adjuvant needs. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 690-699.	2.0	1
5	Sensitivity and Specificity in Urine Bladder Cancer Markers – Is it that Simple?. <i>Bladder Cancer</i> , 2022, 8, 1-4.	0.4	1
6	Diagnostic benefit of multiparametric MRI over contrast-enhanced CT in patients with bladder cancer: A single-center 1-year experience. <i>European Journal of Radiology</i> , 2022, 146, 110059.	2.6	2
7	A non-inferiority comparative analysis of micro-ultrasonography and MRI-targeted biopsy in men at risk of prostate cancer. <i>BJU International</i> , 2022, 129, 648-654.	2.5	14
8	Nomograms including the UBC Rapid test to detect primary bladder cancer based on a multicentre dataset. <i>BJU International</i> , 2022, 130, 754-763.	2.5	6
9	Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA) + androgen deprivation therapy (ADT) by high or low disease volume and progression to mHSPC (M0 at diagnosis) or <i>de novo</i> mHSPC (M1 at diagnosis): Post hoc analysis of the phase 3 ARCHES trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 115-115.	1.6	3
10	The role of single-nucleotide polymorphisms of the 8q24 chromosome region in patients with concomitant bladder and prostate cancer. <i>Scandinavian Journal of Urology</i> , 2022, 56, 126-130.	1.0	1
11	Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1616-1622.	1.6	111
12	The CAG-triplet in the androgen receptor gene and single-nucleotide polymorphisms in androgen pathway genes in patients with concomitant bladder and prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 198.e1-198.e8.	1.6	2
13	Replacing Needle Injection by a Novel Waterjet Technology Grants Improved Muscle Cell Delivery in Target Tissues. <i>Cell Transplantation</i> , 2022, 31, 096368972210809.	2.5	4
14	Elevated Expression of the Immune Checkpoint Ligand CD276 (B7-H3) in Urothelial Carcinoma Cell Lines Correlates Negatively with the Cell Proliferation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4969.	4.1	5
15	CD24: A Marker for an Extended Expansion Potential of Urothelial Cancer Cell Organoids In Vitro?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5453.	4.1	7
16	Urinary Tract Tumor Organoids Reveal Eminent Differences in Drug Sensitivities When Compared to 2-Dimensional Culture Systems. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6305.	4.1	8
17	Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab. <i>Cancers</i> , 2022, 14, 2972.	3.7	13
18	Data-Driven Identification of Biomarkers for In Situ Monitoring of Drug Treatment in Bladder Cancer Organoids. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6956.	4.1	9

#	ARTICLE	IF	CITATIONS
19	The association of germline <i>HSD3B1</i> genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES]. <i>Journal of Clinical Oncology</i> , 2022, 40, 5022-5022.	1.6	0
20	Clinical outcomes and safety of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) in patients aged ≥ 75 and <math>< 75</math> years: ARCHES post hoc analysis. <i>Journal of Clinical Oncology</i> , 2022, 40, 5069-5069.	1.6	2
21	Radiographic progression in the absence of prostate-specific antigen (PSA) progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analysis of ARCHES. <i>Journal of Clinical Oncology</i> , 2022, 40, 5072-5072.	1.6	4
22	Prevalence of DNA damage repair (DDR) alterations in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving enzalutamide (ENZA) or placebo (PBO) plus androgen deprivation therapy (ADT): ARCHES post hoc analysis. <i>Journal of Clinical Oncology</i> , 2022, 40, 5074-5074.	1.6	0
23	The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups. <i>Prostate</i> , 2022, 82, 1237-1247.	2.3	2
24	Enfortumab vedotin – next game-changer in urothelial cancer. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 801-809.	3.1	17
25	Rapid and precise delivery of cells in the urethral sphincter complex by a novel needle-free waterjet technology. <i>BJU International</i> , 2021, 127, 463-472.	2.5	7
26	A Modified Neobladder Technique: The ‘‘Pouch’’ Illustration of Surgical Approach and Tricks. <i>Urology</i> , 2021, 147, 318.	1.0	2
27	Everolimus after failure of one prior VEGF –targeted therapy in metastatic renal cell carcinoma: Final results of the MARC –2 trial. <i>International Journal of Cancer</i> , 2021, 148, 1685-1694.	5.1	7
28	Urinary biomarkers in bladder cancer: A review of the current landscape and future directions. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 41-51.	1.6	103
29	Role of Multiparametric Magnetic Resonance Imaging in Predicting Pathologic Outcomes in Prostate Cancer. <i>World Journal of Men’s Health</i> , 2021, 39, 38.	3.3	2
30	Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB. <i>World Journal of Urology</i> , 2021, 39, 2953-2960.	2.2	5
31	Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with <i>de novo</i> (M1) metastatic hormone-sensitive prostate cancer (mHSPC) versus progression to mHSPC (M0): Post hoc analysis of the phase III ARCHES trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 102-102.	1.6	4
32	The prognostic value of fat invasion and tumor expansion in the hilar veins in pT3a renal cell carcinoma. <i>World Journal of Urology</i> , 2021, 39, 3367-3376.	2.2	6
33	Minimal-invasive management of urological complications after kidney transplantation. <i>International Urology and Nephrology</i> , 2021, 53, 1267-1277.	1.4	10
34	Utility of pT3 substaging in lymph node-negative urothelial carcinoma of the bladder: do pathologic parameters add to prognostic sub-stratification?. <i>World Journal of Urology</i> , 2021, 39, 4021-4027.	2.2	1
35	Treatment of Stress Urinary Incontinence with Muscle Stem Cells and Stem Cell Components: Chances, Challenges and Future Prospects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3981.	4.1	14
36	Injection of Porcine Adipose Tissue-Derived Stromal Cells by a Novel Waterjet Technology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3958.	4.1	3

#	ARTICLE	IF	CITATIONS
37	Reply by Authors. Journal of Urology, 2021, 205, 1371-1371.	0.4	0
38	The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES.. Journal of Clinical Oncology, 2021, 39, 5071-5071.	1.6	1
39	Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses. Journal of Urology, 2021, 205, 1361-1371.	0.4	25
40	Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study). Cancers, 2021, 13, 2594.	3.7	2
41	Large Animal Models for Investigating Cell Therapies of Stress Urinary Incontinence. International Journal of Molecular Sciences, 2021, 22, 6092.	4.1	4
42	Micro-Ultrasound: a way to bring imaging for prostate cancer back to urology. Prostate International, 2021, 9, 61-65.	2.3	8
43	Pembrolizumab for the treatment of renal cell carcinoma. Expert Opinion on Biological Therapy, 2021, 21, 1157-1164.	3.1	2
44	Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. European Urology, 2021, 80, 703-711.	1.9	108
45	Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials. Prostate Cancer and Prostatic Diseases, 2021, , .	3.9	2
46	Comparison of the metabolome in urine prior and eight weeks after radical prostatectomy uncovers pathologic and molecular features of prostate cancer. Journal of Pharmaceutical and Biomedical Analysis, 2021, 205, 114288.	2.8	3
47	The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials. Cancers, 2021, 13, 5872.	3.7	3
48	Application of Artificial Intelligence to Overcome Clinical Information Overload in Urologic Cancer. BJU International, 2021, , .	2.5	3
49	Characterization of Genetic Heterogeneity in Recurrent Metastases of Renal Cell Carcinoma. Cancers, 2021, 13, 6221.	3.7	1
50	The prognostic impact of hexaminolevulinate-based bladder tumor resection in patients with primary non-muscle invasive bladder cancer treated with radical cystectomy. World Journal of Urology, 2020, 38, 397-406.	2.2	8
51	Prognostic impact of tumor-associated immune cell infiltrates at radical cystectomy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 4.e7-4.e15.	1.6	2
52	Immune checkpoint inhibition for the treatment of renal cell carcinoma. Expert Opinion on Biological Therapy, 2020, 20, 83-94.	3.1	14
53	Re: Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-resistant Prostate Cancer. European Urology, 2020, 77, 131-132.	1.9	4
54	A novel waterjet technology for transurethral cystoscopic injection of viable cells in the urethral sphincter complex. Neurourology and Urodynamics, 2020, 39, 594-602.	1.5	13

#	ARTICLE	IF	CITATIONS
55	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer – An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	1.9	132
56	Increased Expressions of Matrix Metalloproteinases (MMPs) in Prostate Cancer Tissues of Men with Type 2 Diabetes. <i>Biomedicines</i> , 2020, 8, 507.	3.2	5
57	Characterization of Hormone-Dependent Pathways in Six Human Prostate-Cancer Cell Lines: A Gene-Expression Study. <i>Genes</i> , 2020, 11, 1174.	2.4	4
58	Transcript Levels of Aldo-Keto Reductase Family 1 Subfamily C (AKR1C) Are Increased in Prostate Tissue of Patients with Type 2 Diabetes. <i>Journal of Personalized Medicine</i> , 2020, 10, 124.	2.5	5
59	An evaluation of avelumab for the treatment of genitourinary tumors. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 971-979.	3.1	4
60	Prognostic significance of previous tonsillectomy after radical cystectomy for bladder cancer. <i>Scandinavian Journal of Urology</i> , 2020, 54, 297-303.	1.0	0
61	Re: Randomized Trial of Partial Gland Ablation with Vascular Targeted Phototherapy Versus Active Surveillance for Low Risk Prostate Cancer: Extended Followup and Analyses of Effectiveness. <i>European Urology</i> , 2020, 77, 657-658.	1.9	0
62	Human Prostate Cancer Is Characterized by an Increase in Urea Cycle Metabolites. <i>Cancers</i> , 2020, 12, 1814.	3.7	37
63	Impact of Histopathological Prostate Inflammation on Urine-Based Prostate Cancer Prediction Using the Prostate Cancer Gene 3 Score. <i>Urologia Internationalis</i> , 2020, 104, 483-488.	1.3	0
64	Enzalutamide plus androgen-deprivation therapy in hormone-sensitive prostate cancer: new perspectives from a current Phase III clinical trial. <i>Future Oncology</i> , 2020, 16, 1511-1523.	2.4	1
65	Regenerative medicine and injection therapies in stress urinary incontinence. <i>Nature Reviews Urology</i> , 2020, 17, 151-161.	3.8	20
66	Toward noninvasive follow-up of low-risk bladder cancer – Rationale and concept of the UroFollow trial*. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 886-895.	1.6	22
67	Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. <i>European Urology</i> , 2020, 78, 603-614.	1.9	30
68	Clinical Parameters Outperform Molecular Subtypes for Predicting Outcome in Bladder Cancer: Results from Multiple Cohorts, Including TCGA. <i>Journal of Urology</i> , 2020, 203, 62-72.	0.4	33
69	Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review. <i>World Journal of Men's Health</i> , 2020, 38, 151.	3.3	7
70	Efficacy of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES <i>post hoc</i> analyses.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5547-5547.	1.6	1
71	Urothelial Cancer of the Upper Urinary Tract. , 2020, , 539-550.		0
72	Bone Target Therapy in Urologic Malignancies. , 2019, , 77-93.		0

#	ARTICLE	IF	CITATIONS
73	ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2974-2986.	1.6	643
74	Preservation of the bladder, but at what cost?. <i>Translational Andrology and Urology</i> , 2019, 8, S474-S475.	1.4	0
75	SIUâ€™ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 61-83.	2.2	40
76	Assessment of concomitant non-oncologic medication in patients with surgically treated renal cell carcinoma: impact on prognosis, cell-cycle progression and proliferation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1835-1843.	2.5	12
77	NLRP3/IL1Î² inflammasome associated with the aging bladder triggers bladder dysfunction in female rats. <i>Molecular Medicine Reports</i> , 2019, 19, 2960-2968.	2.4	10
78	Intention-to-Treat Analysis of ⁶⁸ Ga-PSMA and ¹¹ C-Choline PET/CT Versus CT for Prostate Cancer Recurrence After Surgery. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1359-1365.	5.0	29
79	Antitumour activity of <i>Helix</i> hemocyanin against bladder carcinoma permanent cell lines. <i>Biotechnology and Biotechnological Equipment</i> , 2019, 33, 20-32.	1.3	10
80	Stress urinary incontinence and regenerative medicine. <i>Current Opinion in Urology</i> , 2019, 29, 394-399.	1.8	5
81	Intratumoral Heterogeneity Determines the Expression of mTOR-pathway Proteins in Prostate Cancer. <i>Disease Markers</i> , 2019, 2019, 1-8.	1.3	1
82	Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer. <i>World Journal of Urology</i> , 2019, 37, 1773-1784.	2.2	22
83	Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. <i>European Urology</i> , 2019, 75, 604-611.	1.9	197
84	Can contrast-enhanced ultrasound and acoustic radiation force impulse imaging characterize CT-indeterminate renal masses? A prospective evaluation with histological confirmation. <i>World Journal of Urology</i> , 2019, 37, 1339-1346.	2.2	15
85	Results of a Phase 1/2 Study in Metastatic Renal Cell Carcinoma Patients Treated with a Patient-specific Adjuvant Multi-peptide Vaccine after Resection of Metastases. <i>European Urology Focus</i> , 2019, 5, 604-607.	3.1	17
86	Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 687-687.	1.6	22
87	Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer. <i>Asian Journal of Andrology</i> , 2019, 21, 12.	1.6	5
88	ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5048-5048.	1.6	2
89	Metabolic syndrome is not associated with greater evidences of proliferative inflammatory atrophy and inflammation in patients with suspected prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 240.e21-240.e26.	1.6	3
90	Higher prevalence of lymph node metastasis in prostate cancer in patients with diabetes. <i>Endocrine-Related Cancer</i> , 2018, 25, L19-L22.	3.1	19

#	ARTICLE	IF	CITATIONS
91	Androgen receptor overexpression in prostate cancer in type 2 diabetes. <i>Molecular Metabolism</i> , 2018, 8, 158-166.	6.5	22
92	Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer. <i>BJU International</i> , 2018, 122, 152-159.	2.5	21
93	Peptide-Based Sandwich Immunoassay for the Quantification of the Membrane Transporter Multidrug Resistance Protein 1. <i>Analytical Chemistry</i> , 2018, 90, 5788-5794.	6.5	6
94	Perioperative morbidity, bowel function and oncologic outcome after radical cystectomy and ileal orthotopic neobladder reconstruction: Studer-pouch versus I-pouch. <i>European Journal of Surgical Oncology</i> , 2018, 44, 178-184.	1.0	14
95	The prognostic effect of salvage surgery and radiotherapy in patients with recurrent primary urethral carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 10.e7-10.e14.	1.6	12
96	A Subpopulation of Stromal Cells Controls Cancer Cell Homing to the Bone Marrow. <i>Cancer Research</i> , 2018, 78, 129-142.	0.9	32
97	Urethral recurrence after radical cystectomy for urothelial carcinoma: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 54-59.	1.6	28
98	Targeted vs systematic robot-assisted transperineal magnetic resonance imaging-transrectal ultrasonography fusion prostate biopsy. <i>BJU International</i> , 2018, 121, 791-798.	2.5	22
99	A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 43-53.	1.6	113
100	Immunotherapy for kidney cancer. <i>Current Opinion in Urology</i> , 2018, 28, 8-14.	1.8	37
101	Impact of variant microscopic interpretation of the uCyt+ immunocytological urine test for the detection of bladder cancer. <i>Diagnostic Cytopathology</i> , 2018, 46, 111-116.	1.0	5
102	Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice. <i>BJU International</i> , 2018, 121, 84-92.	2.5	22
103	Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2746-2755.	4.1	53
104	Trimodal therapy for muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1219-1229.	2.4	9
105	Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases. <i>Disease Markers</i> , 2018, 2018, 1-5.	1.3	9
106	Performance of Urinary Markers for Detection of Upper Tract Urothelial Carcinoma: Is Upper Tract Urine More Accurate than Urine from the Bladder?. <i>Disease Markers</i> , 2018, 2018, 1-5.	1.3	19
107	Suture causing urethral meatus stricture: A novel animal model of partial bladder outlet obstruction. <i>Neurourology and Urodynamics</i> , 2018, 37, 2088-2096.	1.5	7
108	Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma. <i>BMC Medicine</i> , 2018, 16, 108.	5.5	11

#	ARTICLE	IF	CITATIONS
109	Transketolase like 1 (TKTL1) expression alterations in prostate cancer tumorigenesis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 472.e21-472.e27.	1.6	13
110	Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?. Expert Review of Anticancer Therapy, 2017, 17, 357-368.	2.4	11
111	Total proximal ureter substitution using buccal mucosa. International Journal of Urology, 2017, 24, 320-323.	1.0	14
112	Is The Cancer Genome Atlas (TCGA) bladder cancer cohort representative of invasive bladder cancer?. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 458.e1-458.e7.	1.6	7
113	Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience. Therapeutic Advances in Urology, 2017, 9, 81-88.	2.0	27
114	Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. European Urology, 2017, 72, 477-481.	1.9	36
115	The Value and Evaluability of the PCA3 Urine Assay in Prostate Carcinoma is Independent of the Tumor Localization. Advances in Therapy, 2017, 34, 966-974.	2.9	2
116	Comparison of different concepts for interpretation of chromosomal aberrations in urothelial cells detected by fluorescence in situ hybridization. Journal of Cancer Research and Clinical Oncology, 2017, 143, 677-685.	2.5	16
117	Precise injection of human mesenchymal stromal cells in the urethral sphincter complex of Göttingen minipigs without unspecific bulking effects. Neurourology and Urodynamics, 2017, 36, 1723-1733.	1.5	16
118	Establishing and monitoring of urethral sphincter deficiency in a large animal model. World Journal of Urology, 2017, 35, 1977-1986.	2.2	8
119	Ex vivo γ H2AX radiation sensitivity assay in prostate cancer: Inter-patient and intra-patient heterogeneity. Radiotherapy and Oncology, 2017, 124, 386-394.	0.6	18
120	Effect of radical prostatectomy on levels of cancer related epitopes in circulating macrophages of patients with clinically localized prostate cancer. Prostate, 2017, 77, 1251-1258.	2.3	5
121	Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. Clinical Cancer Research, 2017, 23, 6487-6497.	7.0	121
122	Adjuvant Treatment of High-risk Renal Cell Carcinoma: Leaving the Desert?. European Urology, 2017, 71, 695-696.	1.9	14
123	Assessing the reproducibility of high definition urethral pressure profilometry and its correlation with an air-charged system. Neurourology and Urodynamics, 2017, 36, 1292-1300.	1.5	2
124	Collagen cell carriers seeded with human urothelial cells for urethral reconstructive surgery: first results in a xenograft minipig model. World Journal of Urology, 2017, 35, 1125-1132.	2.2	19
125	Comparison of ^{68}Ga -labelled PSMA-11 and ^{11}C -choline in the detection of prostate cancer metastases by PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 92-101.	6.4	237
126	Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy. European Urology, 2017, 71, 545-557.	1.9	72

#	ARTICLE	IF	CITATIONS
127	AGS-003 combined with sunitinib for the precision treatment of metastatic renal cell carcinoma. Expert Review of Precision Medicine and Drug Development, 2017, 2, 243-248.	0.7	0
128	DNA methylation signature for the assessment of metastatic risk in primary renal cell cancer.. Journal of Clinical Oncology, 2017, 35, 516-516.	1.6	2
129	Minimal Invasive Cystometry and Intra-Abdominal Pressure Assessments in Rodents: A Novel Animal Study. Medical Science Monitor, 2017, 23, 2500-2507.	1.1	2
130	Laparoscopic versus Open Partial Nephrectomy: Comparison of Overall and Subgroup Outcomes. Anticancer Research, 2017, 37, 261-266.	1.1	11
131	Prediction of Postoperative Risks in Laparoscopic Partial Nephrectomy Using RENAL, Mayo Adhesive Probability and Renal Pelvic Score. Anticancer Research, 2017, 37, 1369-1374.	1.1	16
132	Bone Target Therapy in Urologic Malignancies. , 2017, , 1-16.		0
133	The Impact of Blue Light Cystoscopy with Hexaminolevulinat (HAL) on Progression of Bladder Cancer â€“ A New Analysis. Bladder Cancer, 2016, 2, 273-278.	0.4	46
134	High definition urethral pressure profilometry: Evaluating a novel microtip catheter. Neurourology and Urodynamics, 2016, 35, 888-894.	1.5	7
135	The current status of checkpoint inhibitors in metastatic bladder cancer. Clinical and Experimental Metastasis, 2016, 33, 629-635.	3.3	11
136	Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design. Oncolmmunology, 2016, 5, e1204504.	4.6	19
137	Enhanced Recovery After Robot-assisted Radical Cystectomy: EAU Robotic Urology Section Scientific Working Group Consensus View. European Urology, 2016, 70, 649-660.	1.9	114
138	IMA901, a multi-peptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 1599-1611.	10.7	181
139	Metastasectomy for metastatic renal cell carcinoma in the era of modern systemic treatment: Câ€reactive protein is an independent predictor of overall survival. International Journal of Urology, 2016, 23, 916-921.	1.0	12
140	Liquid biopsy: ready to guide therapy in advanced prostate cancer?. BJU International, 2016, 118, 855-863.	2.5	61
141	Systemic anti-CTLA-4 and intravesical Bacilleâ€“Calmetteâ€“Guerin therapy in non-muscle invasive bladder cancer: Is there a rationale of synergism?. Medical Hypotheses, 2016, 92, 57-58.	1.5	7
142	Assessment of a new point-of-care system for detection of prostate specific antigen. BMC Urology, 2016, 16, 4.	1.4	8
143	Signal processing in urodynamics: towards high definition urethral pressure profilometry. BioMedical Engineering OnLine, 2016, 15, 31.	2.7	6
144	Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma. World Journal of Urology, 2016, 34, 97-103.	2.2	51

#	ARTICLE	IF	CITATIONS
145	Prostate tumor overexpressed 1 expression in invasive urothelial carcinoma. Journal of Cancer Research and Clinical Oncology, 2016, 142, 937-947.	2.5	7
146	Algorithm for Optimal Urethral Coverage in Hypospadias and Fistula Repair: A Systematic Review. European Urology, 2016, 70, 293-298.	1.9	45
147	Nodal Clearance Rate and Long-Term Efficacy of "Individualized Sentinel Node" Based Pelvic Intensity Modulated Radiation Therapy for High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 94, 263-271.	0.8	6
148	Re: Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. European Urology, 2016, 69, 538-539.	1.9	3
149	Challenges for Restoration of Lower Urinary Tract Innervation in Patients with Spinal Cord Injury: A European Single-center Retrospective Study with Long-term Follow-up. European Urology, 2016, 69, 771-774.	1.9	10
150	Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy. OncoImmunology, 2016, 5, e1108511.	4.6	41
151	Limited versus extended pelvic lymphadenectomy in patients with bladder cancer undergoing radical cystectomy: Survival results from a prospective, randomized trial (LEA AUO AB 25/02).. Journal of Clinical Oncology, 2016, 34, 4503-4503.	1.6	31
152	Tumor Specific Epigenetic Silencing of Corticotropin Releasing Hormone -Binding Protein in Renal Cell Carcinoma: Association of Hypermethylation and Metastasis. PLoS ONE, 2016, 11, e0163873.	2.5	19
153	Oncologic Impact of Renal Tissue Adjacent to Renal Cell Carcinoma. Anticancer Research, 2016, 36, 2865-9.	1.1	4
154	Current status of robotic assisted radical cystectomy with intracorporeal ileal neobladder for bladder cancer. Journal of Surgical Oncology, 2015, 112, 427-429.	1.7	11
155	Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. , 2015, 3, 26.		206
156	Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies. International Journal of Endocrinology, 2015, 2015, 1-9.	1.5	28
157	Eliminating pulse-induced artifacts in Urethral Pressure data. , 2015, 2015, 2779-83.		6
158	Mesenchymal stromal cells for sphincter regeneration. Advanced Drug Delivery Reviews, 2015, 82-83, 123-136.	13.7	21
159	Expression patterns and prognostic role of transketolase-like 1 in muscle-invasive bladder cancer. World Journal of Urology, 2015, 33, 1403-1409.	2.2	9
160	Best Practices in Robot-assisted Radical Cystectomy and Urinary Reconstruction: Recommendations of the Pasadena Consensus Panel. European Urology, 2015, 67, 363-375.	1.9	158
161	Systematic Review and Cumulative Analysis of Oncologic and Functional Outcomes After Robot-assisted Radical Cystectomy. European Urology, 2015, 67, 402-422.	1.9	199
162	Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. European Urology, 2015, 68, 238-253.	1.9	211

#	ARTICLE	IF	CITATIONS
163	Fluorescence-guided bladder tumour resection: impact on survival after radical cystectomy. <i>World Journal of Urology</i> , 2015, 33, 1429-1437.	2.2	31
164	Feasibility of Penis-Preserving Surgery for Urethral Melanoma: Proposal for a Therapeutic Algorithm. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e411-e413.	1.9	10
165	Survival Prediction of Clear Cell Renal Cell Carcinoma Based on Gene Expression Similarity to the Proximal Tubule of the Nephron. <i>European Urology</i> , 2015, 68, 1016-1020.	1.9	55
166	New technique for needle-less implantation of eukaryotic cells. <i>Cytherapy</i> , 2015, 17, 1655-1661.	0.7	7
167	Muscle-invasive bladder cancer is characterized by overexpression of thymidine kinase 1. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 426.e21-426.e29.	1.6	5
168	Treatment and Outcomes of Urethral Recurrence of Urinary Bladder Cancer in Women after Radical Cystectomy and Orthotopic Neobladder: A Series of 12 Cases. <i>Urologia Internationalis</i> , 2015, 94, 45-49.	1.3	13
169	Residual γ H2AX foci after ex vivo irradiation of patient samples with known tumour-type specific differences in radio-responsiveness. <i>Radiotherapy and Oncology</i> , 2015, 116, 480-485.	0.6	37
170	Technical solutions to improve the management of non-muscle-invasive transitional cell carcinoma: summary of a European Association of Urology Section for Uro-Technology (ESUT) and Section for Uro-Oncology (ESOU) expert meeting and current and future pers. <i>BJU International</i> , 2015, 115, 14-23.	2.5	45
171	Quality of life outcomes after radical cystectomy: long-term standardized assessment of Studer Pouch versus I-Pouch. <i>World Journal of Urology</i> , 2015, 33, 1381-1387.	2.2	14
172	Analysis of Early Morbidity and Functional Outcome of Thulium: Yttrium-Aluminum-Garnet Laser Enucleation for Benign Prostate Enlargement: Patient Age and Prostate Size Determine Adverse Surgical Outcome. <i>Urology</i> , 2015, 85, 182-188.	1.0	33
173	Impact of salvage surgery and radiotherapy on overall survival in patients with recurrent primary urethral cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4568-4568.	1.6	1
174	Rho GDP dissociation inhibitor beta ARHGDI3 in renal cell cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 474-474.	1.6	0
175	Towards a Treatment of Stress Urinary Incontinence: Application of Mesenchymal Stromal Cells for Regeneration of the Sphincter Muscle. <i>Journal of Clinical Medicine</i> , 2014, 3, 197-215.	2.4	15
176	Stepwise Application of Urine Markers to Detect Tumor Recurrence in Patients Undergoing Surveillance for Non-Muscle-Invasive Bladder Cancer. <i>Disease Markers</i> , 2014, 2014, 1-7.	1.3	19
177	Galectin-1 and Galectin-3 mRNA expression in renal cell carcinoma. <i>BMC Clinical Pathology</i> , 2014, 14, 15.	1.8	18
178	Recapitulating the urinary bladderâ€”where are we heading?. <i>Nature Reviews Urology</i> , 2014, 11, 70-71.	3.8	0
179	Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. <i>BJU International</i> , 2014, 113, 11-23.	2.5	274
180	Sampling lattice and signal reconstruction in urodynamics. , 2014, , .		6

#	ARTICLE	IF	CITATIONS
181	Safety of Hexaminolevulinate for Blue Light Cystoscopy in Bladder Cancer. A Combined Analysis of the Trials Used for Registration and Postmarketing Data. <i>Urology</i> , 2014, 84, 122-126.	1.0	18
182	Prospective evaluation of fluorescence-guided cystoscopy to detect bladder cancer in a high-risk population: results from the UroScreen-Study. <i>SpringerPlus</i> , 2014, 3, 24.	1.2	8
183	Evaluation of a new quantitative point-of-care test platform for urine-based detection of bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 337-344.	1.6	36
184	Clinical and Cost Effectiveness of Hexaminolevulinate-guided Blue-light Cystoscopy: Evidence Review and Updated Expert Recommendations. <i>European Urology</i> , 2014, 66, 863-871.	1.9	72
185	Comparative analysis of comorbidity and performance indices for prediction of oncological outcomes in patients with upper tract urothelial carcinoma who were treated with radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1141-1150.	1.6	18
186	Impact of Preoperative Anemia on Oncologic Outcomes of Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. <i>Journal of Urology</i> , 2014, 191, 316-322.	0.4	49
187	GATA5 CpG island hypermethylation is an independent predictor for poor clinical outcome in renal cell carcinoma. <i>Oncology Reports</i> , 2014, 31, 1523-1530.	2.6	15
188	Intracorporeal ileal ureter replacement using laparoscopy and robotics. <i>Central European Journal of Urology</i> , 2014, 67, 420-3.	0.3	21
189	Author's reply. <i>Central European Journal of Urology</i> , 2014, 67, 426.	0.3	0
190	Impact on clinical prognosis using DNA methylation of the SLC16A3 promoter and expression of the human lactate transporter MCT4 in renal cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 452-452.	1.6	0
191	Impact of altered Wnt1/ β -catenin expression on clinicopathology and prognosis in renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 465-465.	1.6	3
192	Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: Results of the international collaboration on primary urethral carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4587-4587.	1.6	1
193	Latissimus Dorsi Detrusor Myoplasty to Restore Voiding in Patients with an Acontractile Bladder â€“ Fact or Fiction?. <i>Current Urology Reports</i> , 2013, 14, 426-434.	2.2	17
194	Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression?. <i>World Journal of Urology</i> , 2013, 31, 345-350.	2.2	22
195	Hexyl Aminolevulinateâ€“Guided Fluorescence Cystoscopy in the Diagnosis and Follow-up of Patients with Nonâ€“Muscle-invasive Bladder Cancer: A Critical Review of the Current Literature. <i>European Urology</i> , 2013, 64, 624-638.	1.9	193
196	ICUD-EAU International Consultation on Bladder Cancer 2012: Radical Cystectomy and Bladder Preservation for Muscle-Invasive Urothelial Carcinoma of the Bladder. <i>European Urology</i> , 2013, 63, 45-57.	1.9	361
197	Impact of different grades of microscopic hematuria on the performance of urine-based markers for the detection of urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1148-1154.	1.6	27
198	Photodynamic Diagnosis of Nonâ€“muscle-invasive Bladder Cancer with Hexaminolevulinate Cystoscopy: A Meta-analysis of Detection and Recurrence Based on Raw Data. <i>European Urology</i> , 2013, 64, 846-854.	1.9	372

#	ARTICLE	IF	CITATIONS
199	Immunotherapy With RNA Vaccination Coding For TAA In Renal Cell Carcinoma: Update On Immunological Responses and Correlation With Survival. <i>Blood</i> , 2013, 122, 1040-1040.	1.4	0
200	Bladder hypocontractilityâ€”extending the indication for LDDM. <i>Nature Reviews Urology</i> , 2012, 9, 231-232.	3.8	2
201	Accurate risk assessment of patients with asymptomatic hematuria for the presence of bladder cancer. <i>World Journal of Urology</i> , 2012, 30, 847-852.	2.2	23
202	Long-Term Decrease in Bladder Cancer Recurrence with Hexaminolevulinat Enabled Fluorescence Cystoscopy. <i>Journal of Urology</i> , 2012, 188, 58-62.	0.4	158
203	Influence of Urinary Tract Instrumentation and Inflammation on the Performance of Urine Markers for the Detection of Bladder Cancer. <i>Urology</i> , 2012, 79, 620-625.	1.0	35
204	Stem cell therapy for voiding and erectile dysfunction. <i>Nature Reviews Urology</i> , 2012, 9, 435-447.	3.8	27
205	Urinary Incontinence and Retention in the Female Neobladder Why Does This Occur and Treatment Options?. <i>Current Bladder Dysfunction Reports</i> , 2012, 7, 309-314.	0.5	3
206	Insulin Receptor Isoforms A and B as well as Insulin Receptor Substrates-1 and -2 Are Differentially Expressed in Prostate Cancer. <i>PLoS ONE</i> , 2012, 7, e50953.	2.5	59
207	Functional Detrusor Myoplasty for Bladder Acontractility: Long-Term Results. <i>Journal of Urology</i> , 2011, 185, 593-599.	0.4	41
208	Treatment of Muscle-invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. <i>European Urology</i> , 2011, 59, 1009-1018.	1.9	570
209	Salvage Lymph Node Dissection in Recurrent Prostate Cancer Patients. <i>European Urology</i> , 2011, 60, 944-945.	1.9	4
210	Radical cystectomy with orthotopic neobladder for invasive bladder cancer: a critical analysis of long term oncological, functional and quality of life results. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2010, 36, 537-547.	1.5	46
211	Hexaminolevulinat Guided Fluorescence Cystoscopy Reduces Recurrence in Patients With Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2010, 184, 1907-1914.	0.4	243
212	Ileal Neobladder and Its Variants. <i>European Urology Supplements</i> , 2010, 9, 745-753.	0.1	40
213	<i>In vitro</i> Myogenic Differentiation of Human Bone Marrowâ€”Derived Mesenchymal Stem Cells as a Potential Treatment for Urethral Sphincter Muscle Repair. <i>Annals of the New York Academy of Sciences</i> , 2009, 1176, 135-143.	3.8	65
214	Editorial Comment. <i>Journal of Urology</i> , 2009, 182, 1317-1317.	0.4	0
215	Should photodynamic diagnosis be standard practice for bladder cancer?. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 697-699.	2.4	3
216	Histological verification of ¹¹ Câ€”cholineâ€”positron emission/computed tomographyâ€”positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. <i>BJU International</i> , 2008, 102, 446-451.	2.5	124

#	ARTICLE	IF	CITATIONS
217	Urinary Diversion. <i>Urology</i> , 2007, 69, 17-49.	1.0	334
218	Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 347-355.	0.8	47
219	Reply to Dr Schrader and Dr Miller's Letter to the Editor re: Udo Nagele, Markus Kuczyk, Aristotelis G. Anastasiadis, Karl-Dietrich Sievert, Jurrg Seibold, Arnulf Stenzl. Radical Cystectomy and Orthotopic Bladder Replacement in Females. <i>Eur Urol</i> 2006;50;249-257. <i>European Urology</i> , 2007, 51, 863-864.	1.9	0
220	Re: Pathologic Guidelines for Orthotopic Urinary Diversion in Women with Bladder Cancer: A Review of the Literature. <i>European Urology</i> , 2007, 51, 849-850.	1.9	0
221	Radical Cystectomy and Orthotopic Bladder Replacement in Females. <i>European Urology</i> , 2006, 50, 249-257.	1.9	25
222	Clinical outcome after cystectomy in patients with lymph node-positive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 871-876.	2.4	5
223	Cystectomy – Technical Considerations in Male and Female Patients. <i>EAU Update Series</i> , 2005, 3, 138-146.	0.5	35
224	Orthotopic bladder reconstruction in women – what we have learned over the last decade. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 47, 147-154.	4.4	33
225	Free neurovascular transfer of latissimus dorsi muscle for the treatment of bladder acontractility: II. Clinical results. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2003, 29, 179-80.	1.5	1
226	The Remnant Urothelium after Reconstructive Bladder Surgery. <i>European Urology</i> , 2002, 41, 124-131.	1.9	67
227	Urethra-sparing cystectomy and orthotopic urinary diversion in women with malignant pelvic tumors. <i>Cancer</i> , 2001, 92, 1864-1871.	4.1	120
228	Reconstruction of the lower urinary tract using autologous muscle transfer and cell seeding: current status and future perspectives. <i>World Journal of Urology</i> , 2000, 18, 44-50.	2.2	20
229	Restoration of voluntary emptying of the bladder by transplantation of innervated free skeletal muscle. <i>Lancet, The</i> , 1998, 351, 1483-1485.	13.7	55
230	Free Neurovascular Transfer of Latissimus Dorsi Muscle to the Bladder. I. Experimental Studies. <i>Journal of Urology</i> , 1997, 157, 1103-1108.	0.4	53
231	Update of urethra-sparing approaches in cystectomy in women. <i>World Journal of Urology</i> , 1997, 15, 134-138.	2.2	62
232	Rationale and Technique of Nerve Sparing Radical Cystectomy Before an Orthotopic Neobladder Procedure in Women. <i>Journal of Urology</i> , 1995, 154, 2044-2049.	0.4	159
233	Lower Urinary Tract Reconstruction Following Cystectomy In Women Using The Kock Ileal Reservoir With Bilateral Ureteroileal Urethrostomy: Initial Clinical Experience. <i>Journal of Urology</i> , 1994, 152, 1404-1408.	0.4	115